Immunovative has invested in developing in-house capability for manufacturing of our unique products developed from the Mirror EffectTM technology platform. The production of living cell products derived from normal blood donors is a challenge. In order for products produced from a blood donor to become biological drugs, as opposed to just a medical process, the products must be able to consistently meet pre-determined safety, identity and functional characteristics. There can be little deviation in the final product derived from different donors. In addition, the pre-defined characteristics must be preserved after inventory storage and shipping until the product reaches the patient. We have integrated a team of professionals in cell culture, immunology, bioengineering and logistics with facilities, equipment and a quality team to create, validate and operate a biological manufacturing operation that complies with international standards for Good Manufacturing Practices (GMP). Materials used in the manufacturing process can be traced from “vein-to-vein”. All operations are conducted in accordance with written instructions. Quality and safety are designed into every product.